Estrogen for Health & Longevity - Quick Reference Sheet
evipedia.aidev
← Back

Estrogen for Health & Longevity

Created on 08/04/2026 – Quick Reference based on Evidence Review created using AI4L / Grok 4 – Audit

Skin-delivered estrogen with a uterus-protecting hormone when needed is strongest for hot flashes, night sweats, and vaginal dryness, and highly effective for bone and fractures. Exploratory evidence suggests better heart outcomes near menopause; oral late starts raise stroke and clot risk; combined oral use raises breast cancer with longer use. Effects depend on age, how taken, dose, and personal risk. (Full Review)

Protocol

Systemic dose
Transdermal 17β-estradiol 0.025–0.05 mg/day
Patch, gel, or cream; lowest effective dose; titrate to symptoms
Intact uterus
Oral micronized progesterone 100–200 mg at night
Or levonorgestrel intrauterine device for endometrial protection; not needed after hysterectomy
Initiation window
Near menopause (age <60 or <10 years post-menopause)
For premature ovarian insufficiency, replacement often continues to ~50–52 years
Time to effect
Hot flashes / night sweats
Days to 4 weeks
Full effect by 8–12 weeks
Bone density
1–2 years
Measurable change on bone density scan
Vaginal / urinary symptoms
4–12 weeks
Local or systemic therapy for dryness and urinary symptoms

Benefits

Contraindications
  • Current or history of estrogen-sensitive breast cancer
  • Active or recent venous thromboembolism / pulmonary embolism
  • Known thrombophilia with high risk
  • Active arterial thromboembolic disease (e.g., recent myocardial infarction or stroke)
  • Unexplained genital bleeding
  • Active liver disease
  • Known or suspected estrogen-dependent malignancy
  • Pregnancy
    •
Key Interactions
  • CYP3A4 inducers (rifampin, carbamazepine, St. John’s wort)
  • CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, grapefruit juice)
  • Thyroid hormone (levothyroxine)
  • Anticoagulants / antiplatelets (e.g., warfarin, apixaban, aspirin, clopidogrel)
  • Corticosteroids (e.g., prednisone, dexamethasone) and some anticonvulsants (e.g., phenytoin, phenobarbital)
  • High-dose NSAIDs (e.g., ibuprofen, naproxen)
  • Estrogenic or clotting-active supplements (high-dose phytoestrogens, black cohosh, high-dose vitamin E)
  • Antihypertensives with additive fluid effects (e.g., lisinopril, amlodipine)
    •

Risk & Side Effects

  • High: Venous thromboembolism with oral route; stroke; breast cancer with combined estrogen–progestin
    •
  • Medium: Gallbladder disease; endometrial hyperplasia and cancer with unopposed estrogen and intact uterus; cardiovascular events with late initiation or secondary prevention; long-term cognitive harm from late-life initiation
    •
  • Low: Breast tenderness, spotting, headache, nausea, and fluid retention; mood changes and migraine precipitation; oral-route triglyceride elevation; ovarian cancer with longer systemic use
    •
  • Speculative: [risks_speculative]
    •

Monitoring

Marker Target Why
Estradiol (serum) ~50–100+ pg/mL (protocol-dependent) Confirms absorption; guides titration
FSH Falling levels may accompany adequate replacement Context for ovarian status
Progesterone Detectable if oral micronized progesterone used Adherence/absorption check
Blood pressure <120–130 / <80 mmHg individualized Stroke risk management
Lipid panel LDL, HDL, TG in optimal cardiometabolic ranges Cardiovascular risk; oral estrogen may raise triglycerides
Fasting glucose / HbA1c Fasting glucose ~70–90 mg/dL; HbA1c in optimal range Metabolic risk around menopause
TSH Often ~0.5–2.5 mIU/L Oral estrogen raises thyroxine-binding globulin; may need levothyroxine adjustment
Mammography / breast imaging Age- and risk-appropriate schedule Breast cancer surveillance

Cadence: 6–12 weeks after initiation or dose change, then every 6–12 months once stable

Qualitative Assessment

  • Fewer and milder hot flashes / night sweats
  • Improved sleep continuity
  • Better vaginal comfort and sexual function if genitourinary symptoms were present
  • Stable or improved energy and exercise tolerance
  • Maintained or improved bone density on a bone-density scan over 1–2 years
  • Acceptable side-effect profile (minimal breast pain, controlled bleeding pattern)
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.